Research: Parkinsons Mechanism Analysis

Computational elemental-overlap research from the Alchemy Data V2 system — 29 compound candidates and 16 mechanism categories tied to Parkinson's disease biology, filed under USPTO 19/445,644

29 candidate compounds. 16 mechanism categories. Computational elemental-overlap, openly published, filed under USPTO 19/445,644.

Research: Parkinsons Mechanism Analysis is the productised acquisition of Project 12 — a computational research package built on the Alchemy Data V2 elemental-analysis system. It identifies elemental compositions whose constituents overlap with documented Parkinson's mechanisms (dopamine synthesis cofactors, alpha-synuclein clearance, mitochondrial complex support, glutathione system, SOD enzymes, BDNF). The findings include the NAC/Glutathione pathway (rated A-grade by the system based on existing human clinical trial evidence in the literature) and a novel zinc-based formulation. The work is the subject of US patent application 19/445,644.

Findings — what's in the package

• 29 compound candidates identified through Alchemy Data V2 elemental-overlap search.
• NAC / Glutathione pathway — A-grade rating from the system based on existing human clinical trial evidence in the published literature.
• Novel zinc-based formulation — one of the candidate composition families surfaced by the analysis.
• 16 mechanism categories identified through elemental-overlap analysis.
• Top-line statistics: candidate scoring, transformation pathways, synthesis methods, literature cross-references.

Target mechanisms (per the Parkinson's literature)

Primary:

• Dopamine synthesis support — tyrosine hydroxylase requires iron cofactor; dopamine beta-hydroxylase requires copper cofactor.
• Dopamine neuron regeneration — promoting new dopaminergic neuron growth in substantia nigra.
• Dopamine transporter function — supporting dopamine reuptake (zinc-dependent).

Secondary:

• Glutathione system support — major antioxidant system in Parkinson's; glutathione depletion is documented.
• Alpha-synuclein regulation — preventing or clearing alpha-synuclein aggregates (Lewy bodies).
• Mitochondrial complex support — iron-sulfur clusters for mitochondrial function.
• ATP synthesis support — mitochondrial energy production.
• SOD enzyme support — copper-zinc superoxide dismutase.
• Neuroinflammation reduction, oxidative stress mitigation, BDNF enhancement.

Methodology — what this is and isn't

The Alchemy Data V2 system is a correlation-finding tool. It searches elemental compositions and ranks them by overlap with mechanism categories documented in the published literature. It is not a clinical drug discovery pipeline. Discovery scores reflect database coverage and elemental match, not therapeutic probability. The bundled METHODOLOGY.md spells out exactly what the system does and does not establish.

The candidate compounds have not been synthesized for this project, have not been tested in humans, and have not been approved for medical use by any regulator. The package is for computational-research use, IP licensing, and follow-on lab work by qualified investigators.

Patent foundation

What ships in the package

• README.md with the full overview and findings statistics.
• PARKINSONS_CURE_PATENT_APPLICATION.md — the patent application text as filed.
• PATENT_FILING_RECEIPT.md — the USPTO filing receipt record.
• USPTO_FORMS directory and USPTO_REQUIRED_FORMS_LIST.md — the supporting filing forms.
• findings/ directory — full report, summary, known-properties report, raw discovery JSON.
• METHODOLOGY.md — the Alchemy Data V2 methodology explanation.
• SAFETY_DISCLAIMER.md — safety warnings and known toxicity considerations.
• Patent drawings (4 SVGs) — chemical structures, synthesis scheme, coordination structures, pharmaceutical formulations.
• Research reference chart (11×17 SVG).
• CITATION.cff, LICENSE, IP_NOTICE.md, CHANGELOG.md, MANIFEST.json.

How it's made

The work was conducted by running the Alchemy Data V2 system against the Parkinson's-mechanism category set. The system enumerates elemental compositions, scores them by transformation count and database coverage, and cross-references the top candidates against the published literature. The NAC/Glutathione pathway emerged with an A-grade rating because there is existing human clinical trial evidence in the literature for that pathway in Parkinson's. The novel zinc-based formulation emerged as a separate candidate family. The findings were then written up as a patent application and filed under USPTO 19/445,644.

What it can do

The acquired package delivers the research findings, the patent application text, the supporting filing forms, the methodology, the safety disclaimers, and the open-research license. A buyer can use the findings as input to wet-lab investigation, as input to a downstream drug-discovery pipeline, or as a citable patent-application reference. The buyer also acquires the right to make, build, and copy the package contents.

What this acquisition does not deliver: clinical-trial data (none exists yet for the novel candidates), regulatory approval (none granted), synthesised compound samples (none included), or assignment of the underlying patent application. USPTO 19/445,644 remains the inventor's filed application.

License Terms — What's Granted, What Isn't

The acquisition grants the buyer permission to make, build, and copy the deliverable. It does not transfer the underlying intellectual property:

• Granted: permission to use the findings as research input; permission to copy the documentation; permission to build follow-on research and synthesis work against the candidate compositions.
• Not transferred: USPTO application 19/445,644, the Alchemy Data V2 system itself, trademarks, copyrights. IP remains held by Christopher Gabriel Brown.

Buyers seeking IP assignment rather than make/build/copy permission should contact the inventor directly.

Open computational research. 29 candidates. USPTO 19/445,644 pending. Permission to make, build, and copy.